Atreo Expands RTSM Capabilities for Precision Medicine Clinical Trials
Agile Functionality Address an Unmet Need Within Clinical Development
"Atreo's team has collaborated with several precision medicine sponsor organizations in recent months, and it became clear that an agile RTSM solution to support the nuances of their studies did not exist," said
"RTSM systems have historically lacked out of the box, configurable functionality to support precision medicine, radiopharm, and cell | gene therapy trials," said
Atreo's future RTSM product releases will expand upon its personalized medicine solutions. "Precision medicine focused clinical teams have embraced the guidance of Atreo's team on how to deliver a simplified, intuitive solution for the unique workflows of their trial designs," said
About Atreo (https://atreo.io)
Atreo is a Clinical Technology company, comprised of experienced Clinical Technology experts, that offers the next generation of RTSM platform. Atreo helps Clinical Teams to modernize the RTSM experience with unmatched agility and simplicity by leveraging advanced technology and testing methods. Atreo has addressed all common RTSM pain points. Our solution offers numerous advantages, with a specific emphasis on:
- Speed: 1 - 2 week RTSM build from Kickoff to Go-Live
- Quality Quantified: Modern testing practices mitigating RTSM risk
- Agility: Simplified system changes at no cost and unmatched quality
View original content to download multimedia:https://www.prnewswire.com/news-releases/atreo-expands-rtsm-capabilities-for-precision-medicine-clinical-trials-302183773.html
SOURCE Atreo, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ZETA PHI BETA SORORITY, INCORPORATED TO CONVENE THOUSANDS IN NASHVILLE FOR 2026 GRAND BOULÉ
- Best Network Security in Los Angeles Report by CX Research Institute
- Angie’s Flowers of El Paso Introduces Plant Basket Gifts
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share